What role does risk management play in launch readiness?

Risk management, as outlined in ISO 14971:2019, is integral to launch readiness by ensuring that risks associated with the device's use are identified, evaluated, controlled, and monitored throughout its lifecycle. This includes assessing risks related to manufacturing, post-market surveillance, and cybersecurity, all of which must be addressed before launch.

Is launch readiness a one-time event?

Launch readiness is typically a gate preceding market entry, but the underlying activities and considerations are continuous. Post-market surveillance, regulatory compliance updates, and ongoing supply chain management are perpetual activities that evolve even after initial launch.

All terms

CommercializationHospital Buyer & Reimbursement

Launch Readiness

Cross-functional checklist confirming a product is ready for commercial release.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

Definition

Launch readiness is the structured cross-functional gate that confirms a device is ready for commercial release - regulatory clearance, QMS state, supply capacity, sales training, KOL engagement, reimbursement strategy, and post-market surveillance plan. Readiness covers regulatory clearance, supply and manufacturing scale-up, coding and payment, sales training, complaint handling and post-market surveillance. Teams usually use a cross-functional checklist with go or no-go gates. Gaps in reimbursement or supply are common causes of slow launches.

What the regulation says

Regulators do not explicitly define "Launch Readiness" as a distinct regulatory gate; however, they require manufacturers to demonstrate compliance across various regulatory domains prior to placing a device on the market. For instance, the FDA mandates pre-market approval or clearance (21 CFR Part 807, 21 CFR Part 814), and the EU MDR (Regulation (EU) 2017/745) requires conformity assessment and CE marking. Manufacturers must also maintain a robust Quality Management System (QMS), as per 21 CFR Part 820 or ISO 13485:2016, and have a post-market surveillance plan in place, specified in EU MDR Annex III or FDA’s post-market surveillance regulations (21 CFR Part 822).

What this means in practice

Missing any one element can stall launch. CMO, CCO, and Quality VP typically co-own the gate.

Examples

Before launching a new Class II cardiovascular device, a manufacturer ensured all 510(k) requirements were met, production lines were validated according to 21 CFR 820.75, and a comprehensive sales training program was completed.
A European MedTech company verified that its new in vitro diagnostic (IVD) device had successfully passed its conformity assessment under the EU IVDR, secured manufacturing capacity, and established a detailed post-market performance follow-up plan before commercial release.
Following a software update for an existing medical device, the company confirmed that cybersecurity risk assessments were updated per FDA guidance on Content of Premarket Submissions for Management of Cybersecurity in Medical Devices, and the updated software was verified and validated before deployment to market deployment.

Common pitfalls

•Assuming regulatory clearance or approval alone signifies launch readiness without considering other critical elements.
•Failing to integrate regulatory and quality milestones into the overall launch readiness checklist.
•Underestimating the resources and time required for effective sales force training and post-market surveillance infrastructure.
•Neglecting to update launch readiness criteria based on evolving regulatory requirements or market conditions.

Frequently asked questions

Launch readiness heavily relies on a mature QMS that ensures all design, manufacturing, and post-market activities comply with regulatory requirements. A QMS provides the documented processes and controls necessary to consistently produce safe and effective devices, which is a prerequisite for market entry.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Quality & Risk

Design History File(DHF)

Compilation of records describing the design history of a finished device.

Post-Market

Post-Market Surveillance(PMS)

Activities to monitor device safety and performance after market release.

Latest in MedTech

Sources

4 sources

Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 2Regulator guidance and consensus· 1Tier 4Trade press and expert commentary· 3

Link health: 4 verified· last checked 2026-06-20· added official documents checked 2026-11-01

AdvaMed·2AHRMM·1U.S. Food and Drug Administration·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Commercialization0 / 23

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Commercialization
Sources: 4
Updated: 5/5/2026

Compare with another term

Learn in 60 seconds

Cross-functional checklist confirming a product is ready for commercial release.

·Missing any one element can stall launch.
·CMO, CCO, and Quality VP typically co-own the gate.
·Readiness covers regulatory clearance, supply and manufacturing scale-up, coding and payment, sales training, complaint handling and post-market surveillance.

Remember this

Watch out: Assuming regulatory clearance or approval alone signifies launch readiness without considering other critical elements.

Related terms

You may also need

Auto-suggested from Commercialization and shared keywords.

All Commercialization terms